The ABCD2 score was developed to triage patients with transient ischaemic attack according to the risk of experiencing a stroke in the next few hours or days. However, a new systematic review and meta-analysis on the ABCD2 score gives us considerable cause to rethink its value for clinical situations.
This is a preview of subscription content, log in via an institution to check access.
References
Rothwell, P. M. et al. A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack. Lancet 366, 29–36 (2005).
Johnston, S. C. et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 369, 283–292 (2007).
Coutts, S. B. et al. An improved scoring system for identifying patients at high early risk of stroke and functional impairment after an acute transient ischemic attack or minor stroke. Int. J. Stroke 3, 3–10 (2008).
Weimar, C. et al. Prediction of recurrent stroke and vascular death in patients with transient ischemic attack or nondisabling stroke: a prospective comparison of validated prognostic scores. Stroke 41, 487–493 (2010).
Wardlaw, J. M. et al. ABCD2 score and secondary stroke prevention: meta-analysis and effect per 1,000 patients triaged. Neurology 85, 373–380 (2015).
Easton, J. D. et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke 40, 2276–2293 (2009).
Lavallee, P. C. et al. A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects. Lancet Neurol. 6, 953–960 (2007).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
H.-C.D. has received honoraria for participation in clinical trials, contribution to advisory boards or oral presentations from: Abbott, Allergan, AstraZeneca, Bayer Vital, BMS, Boehringer Ingelheim, CoAxia, Corimmun, Covidien, Daiichi-Sankyo, D-Pharm, Fresenius, GlaxoSmithKline, Janssen-Cilag, Johnson & Johnson, Knoll, Lilly, MSD, Medtronic, MindFrame, Neurobiological Technologies, Novartis, Novo-Nordisk, Paion, Parke-Davis, Pfizer, Sanofi-Aventis, Schering-Plough, Servier, Solvay, St. Jude, Syngis, Talecris, Thrombogenics, WebMD Global, Wyeth and Yamanouchi. Financial support for his research projects was provided by AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Lundbeck, Novartis, Janssen-Cilag, Sanofi-Aventis, Syngis and Talecris. He has no ownership interest and does not own stocks in any pharmaceutical company. Within the past year, H.-C.D. has served as an editor for Aktuelle Neurologie, Arzneimitteltherapie, Kopfschmerznews, Stroke News and the Treatment Guidelines of the German Neurological Society, as co-editor of Cephalalgia, and on the editorial boards of The Lancet Neurology, Stroke, European Neurology and Cerebrovascular Disorders. B.F. has received honoraria from Sanofi and Bayer HealthCare.
Rights and permissions
About this article
Cite this article
Diener, HC., Frank, B. Stroke prevention—time to say goodbye to the ABCD2 score?. Nat Rev Neurol 11, 552–553 (2015). https://doi.org/10.1038/nrneurol.2015.156
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2015.156
- Springer Nature Limited